M&A

J&J’s DePuy Synthes buys spinal tech dev Sentio
J&J’s DePuy Synthes buys spinal tech dev Sentio
Mass Device
JNJ
DePuy Synthes
M&A
Sentio
devices
Flag link:
2 Pharma Buyout Targets That May Surprise You
2 Pharma Buyout Targets That May Surprise You
Motley Fool
Biogen
Bristol-Myers Squibb
M&A
MS
multiple sclerosis
immuno-oncology
Flag link:
Is Clovis Oncology A Takeover Candidate?
Is Clovis Oncology A Takeover Candidate?
Seeking Alpha
Clovis Oncology
M&A
rucaparib
PARP inhibitors
Flag link:
Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest
Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest
Motley Fool
Portola Pharmaceuticals
FDA
M&A
Bevyxxa
Flag link:
What we know from BIO2017
What we know from BIO2017
BioPharma Dive
BIO2017
M&A
Novartis
Novo Nordisk
Seattle Genetics
ImmunoCellular Therapeutics
Flag link:
Report: Biopharma dealmaking set to level off
Report: Biopharma dealmaking set to level off
BioPharma Dive
M&A
Flag link:
Analysts: Stryker might not be the only bidder for Novadaq
Analysts: Stryker might not be the only bidder for Novadaq
Endpoints
Stryker
Novadaq
devices
M&A
Flag link:
Stryker to pay $700m for Novadaq
Stryker to pay $700m for Novadaq
Mass Device
Stryker
M&A
Medical Imaging
Novadaq Technologies
devices
Flag link:
Post-boom biotech still has plenty of upbeat trends to boast about
Post-boom biotech still has plenty of upbeat trends to boast about
Endpoints
biotech
funding
M&A
Flag link:
3 Biotech Stocks That Could Become M&A Targets
3 Biotech Stocks That Could Become M&A Targets
Motley Fool
biotech
M&A
Mallinckrodt
Tesaro
Incyte
Flag link:
Johnson & Johnson closes $30B Actelion buyout
Johnson & Johnson closes $30B Actelion buyout
Drug Delivery Business News
JNJ
Actelion
M&A
Flag link:
5 Things You Didn't Know About Eli Lilly and Co
5 Things You Didn't Know About Eli Lilly and Co
Motley Fool
Eli Lilly
drug pricing
M&A
animal health
Flag link:
Is Mallinckrodt in Talks to Be Sold?
Is Mallinckrodt in Talks to Be Sold?
Motley Fool
Mallinckrodt
M&A
Flag link:
Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space
Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space
TheStreet.com
drug pricing
patents
patent cliffs
M&A
generics
Flag link:
Sanofi, Gilead said to be eyeing potential $10B deal for prime cancer target Tesaro
Sanofi, Gilead said to be eyeing potential $10B deal for prime cancer target Tesaro
Fierce Pharma
Sanofi
Gilead Sciences
Tesaro
M&A
Flag link:
What Valeant Pharmaceuticals' Latest Sale Means (and Doesn't Mean) for Investors
What Valeant Pharmaceuticals' Latest Sale Means (and Doesn't Mean) for Investors
Motley Fool
Valeant Pharmaceuticals
investors
M&A
iNova
Flag link:
Johnson & Johnson wins last regulatory nod needed for Actelion acquisition
Johnson & Johnson wins last regulatory nod needed for Actelion acquisition
Drug Delivery Business News
JNJ
Actelion
M&A
EU
Europe
Flag link:
Valeant's iNova Sale Is Much Ado About Nothing
Valeant's iNova Sale Is Much Ado About Nothing
Seeking Alpha
Valeant Pharmaceuticals
iNova
M&A
Flag link:
Why Valeant Pharmaceuticals Intl. Inc. Jumped Higher Today
Why Valeant Pharmaceuticals Intl. Inc. Jumped Higher Today
Motley Fool
Valeant Pharmaceuticals
M&A
iNova
Flag link:
Johnson & Johnson’s $30B buyout suffers setback as Actelion antibiotic fails in one phase 3, succeeds in another
Johnson & Johnson’s $30B buyout suffers setback as Actelion antibiotic fails in one phase 3, succeeds in another
Fierce Biotech
JNJ
Actelion
clinical trials
M&A
antibiotics
cadazolid
Flag link: